IP Library › Assignment 019265/0086
Patent Assignment
Reel/Frame 019265/0086

Security Agreement

Recorded: 2007-05-09 Received: 2007-05-09 Pages: 11
Assignor
RELIANT PHARMACEUTICALS, INC.
Executed: 2007-03-09
Assignee
GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
85 BROAD STREET, NEW YORK, NY, 10004, UNITED STATES
Covered Properties (50)
Methods of Identifying and Treating Patients Likely to Benefit from Omega-3 Fatty Acid Therapy for Dementia, Vascular Dementia, Parkinson's Dementia, Alzheimer's Disease, and/or Mild Cognitive Impairment
Treatment of osteoarthritis with omega-3 fatty acids in individuals who are non-responders or partial responders to non-steroidal anti-inflammatory drug therapy
Application: 60/897,508 →
Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids, and a combination product thereof
Application: 60/880,441 →
Treatment of Fatty Liver
System and Method for Manufacturing Oral Osmotic Drug Delivery Devices, and Methods of Administering Same
Application: 11/615,163 →
Prophylyaxis and treatment of atrial fibrillation with omega-3 fatty acids
Application: 60/860,495 →
Treatment with PPAR agonists and/or antagonists and omega-3 fatty acids, and a combination product thereof
Application: 60/856,832 →
Treatment and prevention of major adverse cardiovascular events or major coronary events by administering omega-3 fatty acids
Application: 60/856,300 →
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering omega-3 fatty acids
Application: 60/856,299 →
Omega-3 fatty acids for reduction of LP-PLA2 levels
Application: 60/852,398 →
Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
Application: 60/851,294 →
Omega-3 fatty acids and dyslipidemic agent for reduction of APO-B levels
Application: 60/850,280 →
Time-sustained-release formulations comprising a beta-blocker
Application: 60/841,496 →
Treatment with pitavastatin and omega-3 fatty acids
Application: 60/840,012 →
Treatment of fatty liver
Application: 60/836,976 →
Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
Application: 11/494,799 →
Treatment of Dihydropyridine Calcium Channel Blockers and Omega-3 Fatty Acids and a Combination Product Thereof
Omega-3 fatty acids for use in treating resistant hypertension
Application: 60/832,156 →
Exhaust filter element
Application: 60/832,123 →
Treatment with Azetidinone-Based Cholesterol Absorption Inhibitors and Omega-3 Fatty Acids and a Combination Product Thereof
Oral osmotic drug delivery system
Application: 11/432,670 →
Oral osmotic drug delivery system
Application: 11/432,661 →
Oral osmotic drug delivery system
Application: 11/432,671 →
Sustained release delivery of isradipine
Application: 11/377,648 →
Coating soft gelatin capsules with active pharmaceutical ingredients
Application: 60/780,306 →
Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
Essential N-3 Fatty Acids in Cardiac Insufficiency and Heart Failure Therapy
Application: 11/333,387 →
Stable Compositions of Fenofibrate with Fatty Acid Esters
Treatment with Omega-3 Fatty Acids and Ppar Agonist and/or Antagonist and a Combination Product Therof
Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
Application: 11/293,513 →
Stable compositions of fenofibrate with fatty acid esters
Application: 11/293,496 →
Oral osmotic drug delivery system
Application: 11/292,305 →
Omega-3 Fatty Acids and Dyslipidemic Agent for Lipid Therapy
Treatment with Omega-3 Fatty Acids and Products Thereof
Application: 11/267,581 →
System and Method of Treatment with Nizatidine
Treating morning migraines with propranolol
Essential Fatty Acids in the Treatment and/or Inhibition of Depression in Patients with Coronary Heart or Artery Disease
Application: 11/106,482 →
Use of Epa and Dha in Secondary Prevention
Application: 10/979,751 →
Pulsatile release histamine H2 antagonist dosage form
Application: 10/875,627 →
Treatment of diabetic patients with omega-3-fatty acids
Application: 10/792,918 →
Pulsatile release histamine H2 antagonist dosage form
Application: 10/689,566 →
Timed Pulsatile Drug Delivery Systems
Application: 10/675,656 →
Deposition Methods and Apparatus
Application: 10/464,468 →
Timed, sustained release systems for propranolol
Application: 10/453,848 →
Extended Release Dosage Forms of Propranolol Hydrochloride
Application: 10/335,295 →
Pulsatile Release Histamine H2 Antagonist Dosage Form
Application: 10/057,759 →
Timed, Sustained Release Systems for Propranolol
Application: 09/971,167 →
Essential Fatty Acids in the Prevention of Cardiovascular Events
Application: 09/869,333 →
Automated Selection of Appropiate Information Based on a Computer User's Context
Application: 09/835,077 →
Timed Pulsatile Drug Delivery Systems
Application: 09/778,645 →